Common Contracts
35 similar Employment Agreement contracts by Xeris Pharmaceuticals Inc, Trade Desk, Inc., Unum Therapeutics, Inc., others
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 5th, 2021 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Employment Agreement (“Agreement”) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the “Parent”), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Company”), and John Shannon (the “Executive”) and is effective as of the closing date of the transactions contemplated by the Transaction Agreement by and among Strongbridge Biopharma plc, the Company and the other parties set forth therein dated May 24, 2021 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 5th, 2021 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Employment Agreement (“Agreement”) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the “Parent”), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Company”), and Steven Pieper (the “Executive”) and is effective as of the closing date of the transactions contemplated by the Transaction Agreement by and among Strongbridge Biopharma plc, the Company and the other parties set forth therein dated May 24, 2021 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 5th, 2021 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Employment Agreement (“Agreement”) is made by and among Xeris Biopharma Holdings, Inc., a Delaware corporation (the “Parent”), Xeris Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Company”), and Paul R. Edick (the “Executive”) and is effective as of the closing date of the transactions contemplated by the Transaction Agreement by and among Strongbridge Biopharma plc, the Company and the other parties set forth therein dated May 24, 2021 (the “Effective Date”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 29th, 2021 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the 28th day of July 2021, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Steven Pieper (the “Executive”) and is effective as of the date written above (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 28th, 2021 • Myomo, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 22nd day of April, 2021 (the “Commencement Date”) between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”’).
EMPLOYMENT AGREEMENTEmployment Agreement • April 28th, 2021 • Myomo, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 22nd day of April, 2021, (the “Commencement Date”) between Myomo, a Delaware corporation (the “Company”), and David Henry (the “Executive”).
AvroBio, Inc. EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2021 • AVROBIO, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 1st day of September, 2018, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Chris Mason (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
AvroBio, Inc. EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2021 • AVROBIO, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 4th day of December 2020, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Diana Escolar, MD (the “Executive”).
EX-10.15 12 d67753dex1015.htm EX-10.15 EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of [ ], 2016 between Intellia Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EX-10.10 10 d547651dex1010.htm EX-10.10 XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Illinois
This Employment Agreement (“Agreement”) is made as of the _________ day of _______________, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ken Johnson (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
RESTORBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2019 • resTORbio, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 8th day of May, 2019, between resTORbio, Inc., a Delaware corporation (the “Company”), and Lloyd Klickstein (the “Executive”) and is effective as of May 13, 2019 (the “Effective Date”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • February 11th, 2019 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the 10th day of June, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Beth Hecht (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 6th, 2019 • Myomo Inc • Orthopedic, prosthetic & surgical appliances & supplies • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 18th day of February, 2019, between Myomo, a Delaware corporation (the “Company”), and David Henry (the “Executive”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 7th, 2019 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the 10th day of June, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Beth Hecht (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2018 • Myomo Inc • Orthopedic, prosthetic & surgical appliances & supplies • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 21st day of June, 2018, between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2018 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the _________ day of _______________, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Barry Deutsch (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2018 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the _________ day of _______________, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and John Shannon (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2018 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the _________ day of _______________, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Paul Edick (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2018 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the _________ day of _______________, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ken Johnson (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
XERIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2018 • Xeris Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This Employment Agreement (“Agreement”) is made as of the _________ day of _______________, 2018, between Xeris Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Steven Prestrelski (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 17th, 2018 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of [ ], 2018 (the “Effective Date”) between Intellia Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 19th, 2018 • Unum Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Unum Therapeutics Inc., a Delaware corporation (the “Company”), and Michael Vasconcelles, M.D. (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 19th, 2018 • Unum Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Unum Therapeutics Inc., a Delaware corporation (the “Company”), and Charles Wilson, Ph.D. (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 19th, 2018 • Unum Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Unum Therapeutics Inc., a Delaware corporation (the “Company”), and Christiana Stamoulis (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2017 • Trade Desk, Inc. • Services-computer programming, data processing, etc. • New York
This Employment Agreement (“Agreement”) is made as of the 11th day of May, 2017, between The Trade Desk, Inc., a Delaware corporation (the “Company”), and Rob Perdue (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2017 • Trade Desk, Inc. • Services-computer programming, data processing, etc. • California
This Employment Agreement (“Agreement”) is made as of the 11th day of May, 2017, between The Trade Desk, Inc., a Delaware corporation (the “Company”), and David Pickles (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2017 • Trade Desk, Inc. • Services-computer programming, data processing, etc. • California
This Employment Agreement (“Agreement”) is made as of the 11th day of May, 2017, between The Trade Desk, Inc., a Delaware corporation (the “Company”), and Jeff Green (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2017 • Trade Desk, Inc. • Services-computer programming, data processing, etc. • New York
This Employment Agreement (“Agreement”) is made as of the 11th day of May, 2017, between The Trade Desk, Inc., a Delaware corporation (the “Company”), and Brian Stempeck (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2017 • Trade Desk, Inc. • Services-computer programming, data processing, etc. • California
This Employment Agreement (“Agreement”) is made as of the 11th day of May, 2017, between The Trade Desk, Inc., a Delaware corporation (the “Company”), and Paul Ross (the “Executive”).
AERPIO PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 17th, 2017 • Aerpio Pharmaceuticals, Inc. • Blank checks • Ohio
This Employment Agreement (“Agreement”) is made as of the day of , 2017, between Aerpio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 27th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of [ ], 2016 between Intellia Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 2nd, 2015 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (the “Agreement”) is made this 26th day of February, 2015 between Repligen Corporation, a Delaware corporation (the “Company”), and Anthony Hunt (the “Executive”) and shall become effective on the date of the Company’s 2015 annual stockholder meeting (the “Effective Date”) except for Section 2(c)(i) which shall be effective as of the date hereof.
EMPLOYMENT AGREEMENTEmployment Agreement • October 5th, 2012 • Lucid Inc • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 1 day of October, 2012, between Lucid, Inc., a New York corporation (the “Company”), and L. Michael Hone (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 5th, 2012 • Lucid Inc • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 1 day of October, 2012, between Lucid, Inc., a New York corporation (the “Company”), and Richard J. Pulsifer (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 8th, 2010 • Aastrom Biosciences Inc • Biological products, (no disgnostic substances) • Michigan
This Employment Agreement (“Agreement”) is made as of the 7th day of June, 2010, between Aastrom Biosciences, Inc., a Michigan corporation (the “Company”), and Scott Durbin (the “Executive”).
